Franz-Werner Haas, CureVac CEO (Christoph Schmidt/picture-alliance/dpa/AP Images)

Cure­Vac touts old­er adult da­ta for GSK-part­nered Covid-19, flu can­di­dates

Ger­many’s Cure­Vac re­port­ed da­ta Mon­day on old­er pa­tients to beef up plans to ad­vance vac­cines for Covid-19 and sea­son­al flu.

In short, the Covid-19 da­ta re­veal the vac­cine can­di­date, known as CV0501 tar­get­ing Omi­cron’s BA.1 vari­ant, boost­ed titers of neu­tral­iz­ing an­ti­bod­ies by 13.3-fold af­ter four weeks at the low­est 12 µg dose lev­el. The da­ta in these co­horts are still small, with 10 pa­tients en­rolled per dose. Some pa­tients al­so re­ceived 25 and 50 µg dos­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.